Piedra, A., Guinart Cuadra, A., Martínez-Recio, S., Mulet Gual, M., Zamora, C., Osuna Gómez, R., . . . Majem Tarruella, M. (2026). Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial).
Citación estilo ChicagoPiedra, Aida|||0000-0002-4795-1132, et al. Baseline PD-L1 Expression On Circulating Immune Cells As a Predictor of Survival and Immune-related Adverse Events in Extensive-stage Small-cell Lung Cancer Patients Treated With Durvalumab and Carboplatin-etoposide (NCT04712903 Trial). 2026.
Cita MLAPiedra, Aida|||0000-0002-4795-1132, et al. Baseline PD-L1 Expression On Circulating Immune Cells As a Predictor of Survival and Immune-related Adverse Events in Extensive-stage Small-cell Lung Cancer Patients Treated With Durvalumab and Carboplatin-etoposide (NCT04712903 Trial). 2026.